FREE ACCESS
5,000–10,000 jobs/day
See all jobs on Scoutfield
Search thousands of fresh jobs every day.
Discover
- Fresh listings
- Fast filters
- No subscription required
Create a free account and start exploring right away.
Core Competencies
Role fitCore Competencies
Use this summary to align your resume positioning with the role.
Demonstrates expertise in small molecule drug discovery, particularly in oncology and immuno-oncology, with a strong foundation in experimental biology and project management. Proven ability to drive drug discovery initiatives through data-driven decision-making and cross-functional collaboration.
Highest-signal resume keywords
PhD In Biological SciencesSmall Molecule Drug DiscoveryOncology And Immuno-Oncology ExpertiseProject Management Across Cross-Functional TeamsData-Driven Decision-Making
ATS Keywords
Tailor your resumeApplicant Tracking System Keywords
Tip: use these terms in your resume and cover letter to boost ATS matches.
Hard Skills
Experimental BiologyWet Lab ExperienceDrug Discovery StrategiesBiomarker StrategiesCompound EvaluationScreening Cascade DesignRisk MitigationProject IdeationContract Research Organization ExperiencePortfolio Management
Soft Skills
Cross-Functional CollaborationData-Driven ThinkingAnticipation Of Scientific Risks
Industry Keywords
Biological TargetsDrug Discovery Value ChainAQEMIA PipelineClinical CandidatesTranslational Biology
About the role
Key responsibilities & impact- Drive the identification, validation, and selection of novel biological targets aligned with clear unmet medical needs
- Contribute to early-stage project ideation through deep biological insight and understanding of the drug discovery value chain
- Guide programs from early discovery into the AQEMIA pipeline, supporting progression toward proof of concept
- Design, implement, and maintain screening cascades for efficient compound evaluation and decision-making
- Partner with project teams to provide biological expertise, identify risks, and support data-driven prioritization
- Manage and collaborate with external CROs to define experimental strategies and generate high-quality, decision-enabling datasets
- Foster cross-functional collaboration across biology, chemistry, modeling, and platform teams
- Help shape AQEMIA’s portfolio of small molecule programs, initially focused on oncology and immuno-oncology
- Work closely with the VP of Biology and multidisciplinary teams to accelerate discovery of clinical candidates
- Provide biological support across the AQEMIA portfolio
Requirements
What you’ll need- PhD in biological sciences (e.g., pharmacology, molecular biology, chemical biology, biochemistry) or equivalent industry experience
- Strong experience in small molecule drug discovery, including progression from hit identification to candidate nomination
- Significant industry experience (typically ~8+ years) in early-stage drug discovery and project ideation
- Demonstrated expertise in oncology and/or immuno-oncology
- Solid understanding of experimental biology, with hands-on wet lab experience to effectively guide and challenge external partners
- Proven ability to apply rigorous, data-driven thinking in a multidisciplinary environment
- Experience working in a Contract Research Organization-based or highly outsourced R&D model
- Track record of contributing to innovative drug discovery strategies aligned with business objectives
- Experience in project or portfolio management across complex, cross-functional teams
- Strong ability to anticipate and mitigate scientific and strategic risks
- Familiarity with translational biology and biomarker strategies
Benefits
Comp & perks- Flexible work arrangements including up to two remote days per week
- Offices in the heart of Paris and London (King’s Cross)
- Opportunity to shape the direction of a fast-growing company and team
- Work alongside an interdisciplinary team combining AI, physics-based modeling, biology, medicinal chemistry, and software engineering
- Professional opportunity to work on novel medicines and impactful drug discovery
- Collaboration with leading pharmaceutical companies
- Strong financial backing from leading European and international investors